Correction: Gandhi et al. Ultrasound-Mediated Blood–Brain Barrier Disruption for Drug Delivery: A Systematic Review of Protocols, Efficacy, and Safety Outcomes from Preclinical and Clinical Studies. Pharmaceutics 2022, 14 , 833.

Autor:	Gandhi, Kushan, Barzegar-Fallah, Anita, Banstola, Ashik, Rizwan, Shakila B., Reynolds, John N. J.
Předmět:	BLOOD-brain barrier
Zdroj:	Pharmaceutics; Jan2023, Vol. 15 Issue 1, p5, 2p
Abstrakt:	HT Agent Manufacturer Shell Composition Gas Core Composition Mean Bubble Diameter (µm) Bubble Concentration (Bubbles/mL) Use in Identified Studies Definity®/Luminity® Lantheus Medical Imaging Lipid C3F8 1.1-3.3 1.2 × 1010 Used in n = 42 preclinical studies (typical doses: 10-20 µL/kg) and n = 6 clinical studies (typical dose: 4 µL/kg) Optison® GE Healthcare Lipid SF6 2.0-4.5 5-8 × 108 Used in n = 14 preclinical studies (typical doses: 50-100 µL/kg but significantly varied in mouse studies) SonoVue®/Lumason® Bracco Diagnostics Lipid-protein C3F8 2.5 1-5 × 108 Used in n = 29 preclinical studies (typical doses 25-150 µL/kg) and n = 2 clinical studies (typical dose: 100 µL/kg) Usphere Prime® Trust Bio-sonics Lipid C3F8 1.0 2.8 × 1010 Used in n = 1 preclinical study Sonazoid® GE Healthcare Lipid C4F10 2.0-3.0 9 × 108 Used in n = 1 preclinical study ht Corrected: Table 3 Comparison of five major commercially available microbubble formulations used in studies for ultrasound-mediated BBB disruption (information sourced from manufacturer) and typical doses. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.